Neoprobe Corp. names vice president, therapeutics.DUBLIN, Ohio--(BUSINESS WIRE)--June 26, 1996--Neoprobe Corp. (NASDAQ/NMS:NEOP NEOP Neoprobe Corporation (stock symbol) NEOP Near Earth Object Program NEOP New England Order of Protection NEOP Nuclear Explosive Operating Procedure , NEOPW) recently named a vice president of therapeutics, Matthew F. Bowman. With more than 20 years of pharmaceutical industry experience, Bowman will coordinate and oversee all activities in the development of Neoprobe's therapeutic products, including activated cellular therapy (ACT), radioimmunotherapy (RIT RIT, n See therapy, regenerative injection. ), and other therapeutic applications of the company's core RIGS(R) technology. Bowman comes to Neoprobe from Pharmacia Inc., formerly of Columbus, where he most recently served as vice president of the Therapeutic Products Division. He also served in senior positions in New Business Development and Licensing for Adria Laboratories, before it was acquired by Pharmacia in 1993. Bowman and his wife and two children reside in Worthington, Ohio. "We are committed to bringing one of the first activated cellular therapies to market, and adding Matt to our team is another significant step toward achieving that goal," said David C. Bupp, president of Neoprobe. "Combined with our recent agreements with Cellcor/Cytogen to provide cell processing and development manufacturing, and with The Dow Chemical Company The Dow Chemical Company (NYSE: DOW TYO: 4850 ) is an American multinational corporation headquartered in Midland, Michigan. Overview The Dow Chemical Company is currently the second largest chemical manufacturer in the World (after BASF)[1]. to secure patents and targeting agents allowing us to develop additional RIGS surgical and therapy products, we believe we are well positioned to fast-track the development of our cellular therapies to improve the standard of care for cancer patients." Bupp continued, "The results of our early clinical trials with RIGS cell therapy show we more than doubled the median life expectancy Life Expectancy 1. The age until which a person is expected to live. 2. The remaining number of years an individual is expected to live, based on IRS issued life expectancy tables. of end-stage colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. patients. We are encouraged by these early results and believe we should accelerate the development of these therapies." Cellular therapies, such as ACT, treat disease by using a patient's own lymphocytes to try to enhance the patient's immune response immune response n. An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes. to cancer. Neoprobe's RIGS/ACT(TM) product, currently in Phase I trials as a treatment for metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. colorectal cancer, is used for patients who have surgery as part of their treatment. RIGS/ACT is unique among cellular therapies in that during a patient's surgery, the company's RIGS system is used to identify otherwise indistinguishable lymph nodes Lymph nodes Small, bean-shaped masses of tissue scattered along the lymphatic system that act as filters and immune monitors, removing fluids, bacteria, or cancer cells that travel through the lymph system. that contain an unusual number of the helper lymphocytes. The lymph nodes are removed, and the lymphocytes are grown outside the body. Within 10 to 14 days, 10 to 100 billion helper cells are infused back into the patient -- with minimal side effects Side effects Effects of a proposed project on other parts of the firm. -- to treat the disease. Radioimmunotherapy, or RIT, is a process for carrying radiation to a specific diseased site with the intention of destroying the diseased tissue with radiation. Currently, Neoprobe is developing its RIT method alongside RIGS/ACT. Neoprobe Corp. is developing and commercializing products based on its proprietary RIGS technology for surgical detection and therapy of cancer. RIGS technology consists of gamma-detecting instruments, cancer-specific targeting agents, and methods for their use. The company's products are intended to improve the standard of care, enhance the quality of life, and extend survival of cancer patients. Neoprobe's first RIGS product for the diagnosis and treatment of colorectal cancer is currently pending regulatory review. CONTACT: Neoprobe Corp., Dublin David C. Bupp or Beth Gonda, 614/793-7500 or Sunrise Financial Group Inc., New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Derek Caldwell, 212/421-1616 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion